Previous close | 140.00 |
Open | 139.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 138.70 - 139.95 |
52-week range | 109.05 - 169.05 |
Volume | |
Avg. volume | 121,402 |
Market cap | 7.939B |
Beta (5Y monthly) | 1.05 |
PE ratio (TTM) | 27.23 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.24 (1.60%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
IMCD_logo Logo IMCD ROTTERDAM, The Netherlands (14 May 2024, 17:00 hrs CEST) – IMCD N.V. ("IMCD" or "Company"), a global leading distribution partner, formulator of speciality chemicals and ingredients, announces that all resolutions proposed to the shareholders Annual General Meeting of shareholders (AGM) held today were adopted. Turn-out was high, with almost 88% of shareholder represented. The resolutions included adoption of the financial statements for the year 2023 and approval of the divi
IMCD_logo Logo IMCD Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months o
Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing Director, IMCD Iberia & Maghreb ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and